Newsroom - CDMO

API Manufacturing / General / Press Releases 08th november 2021

IMPEKK™ for long term medical implants

SEQENS renews its partnership and collaboration with Arkema for the development of its Medical IMPEKK™ PEKK for long-term implants, ideal for use in…

Flow chemistry for efficient and safe synthesis of APIs and intermediates

DOWNLOAD THE PRESS RELEASE Approximately 2,800 active pharmaceutical ingredients (APIs) are currently marketed, 70% of which being synthetic chemical molecules.Their…

API lifecycle management: A CDMO perspective

Didier Combis of Seqens CDMO explains why pharmaceutical companies should consider the specifics of the API when dealing with drug lifecycle management…

Developing Controlled Substances Requires a Whole New Level of Global Diligence

4 Best Practices For Taking the Right Precautions to Develop Safe and Effective controlled Substances By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO…

The Growth of the Generic Drug Marketplace

The Growth of the Generic Drug Marketplace: A Win-Win for Industry and Patients By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO Some…

Faster, Less Costly Cinacalcet Production is Among CDMO Responses to Alleviate Rising Cost of Drugs, Impact of Tariffs

Proprietary intermediates produced in Europe, U.S. rather than imported Across the world, the pressure to cut drug price costs has never been greater.

API Manufacturing 28th october 2019

Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations

Working with Contract Development & Manufacturing Organizations (CDMOs) in Asia has become a popular strategy for European and U.S.-based sponsors because of the associated…

At the Helm of Seqens CDMO North America

I was privileged to work at Sanofi for 21 years, where I had the opportunity to be deeply involved in both technical and…

General 23rd november 2020

SEQENS is committed to the development and production of critical molecules in France

SEQENS has decided to invest €65M to increase its development and production capacities for active ingredients and pharmaceutical intermediates and to accelerate…

A new large scale potent API manufacturing unit at SEQENS Villeneuve-La-Garenne

Shifting needs in the pharmaceutical market are driving a stronger demand for specialized production units to manufacture highly potent active…

General 03rd august 2020

Lahr’s Site: a Seqens CDMO plant.

Founded in 1991, The site of Lahr is part of SEQENS CDMO since mid-2015. The site is specialized in the development and manufacturing…

What kind of chemical structure will help the control of the most life-threatening side effects associated with CoVid-19- Some Salicylamide derivatives appears to be able to compete

DOWNLOAD THE PRESS RELEASE Gérard Guillamot SEQENS Scientific Director Due to the urgency of finding a treatment against CoVid-19,…

New warehouse for active ingredients (API’s) in Lahr

A new warehouse for active ingredients The production of active ingredients on site Lahr has increased steadily over the last years. It was…

The CDMO’s Challenges Developing An Oral Suspension For Children

By, Didier Combis, Commercial Director, Seqens CDMO; Christine Adam, Business Development Manager, Unither Pharmaceuticals and Jean Francois Cordoliani, Site Director, Unither Développement Bordeaux…